Skip to main content
. 2018 Jun 21;6(3):53. doi: 10.3390/diseases6030053

Figure 1.

Figure 1

Timeline of virological kinetic, clinical features, inflammatory response and immunosuppressive/immunomodulatory therapy. Persistence of ZIKV RNA occurred in parallel with progressive clinical deterioration and increased inflammatory response during drug-induced immunosuppression. ZIKV replication was demonstrated in the first serum sample. Cycle threshold: Ct; reactive, if Ct < 38 and not reactive, >38. * Not reactive; DPO: Days post symptom onset; Reference values: CPR–0.0–5.0 mg/dL.